Predictors of achieving modified Health Assessment Questionnaire (mHAQ) < 0.3.
| Predictor | Univariable | Multivariable | ||
|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |
| Female sex | 0.66 | 0.43–1.003 | ||
| Age at initiation, yrs | 0.97 | 0.96–0.99 | 0.98 | 0.96–0.99 |
| BMI > 30 (vs ≤ 30) | 0.51 | 0.33–0.77 | 0.60 | 0.38–0.94 |
| Duration of PsA, yrs | 0.98 | 0.95–1.003 | ||
| Baseline mHAQ (per 0.125)* | 0.80 | 0.73–0.88 | 0.78 | 0.71–0.86 |
| Hypertension | 0.46 | 0.29–0.74 | 0.58 | 0.35–0.98 |
| Cardiovascular disease | 0.33 | 0.11–0.94 | ||
| Diabetes | 0.69 | 0.36–1.32 | ||
| Full-time work | 2.22 | 1.46–3.38 | ||
| Smoker (previous/current) vs never | 0.74 | 0.49–1.12 | ||
| Alcohol (some/any vs none) | 1.69 | 1.11–2.58 | ||
| Current methotrexate | 1.23 | 0.81–1.86 | ||
| Previous biologic use | 0.53 | 0.35–0.81 | 0.56 | 0.36–0.87 |
| College education | 1.06 | 0.69–1.63 | ||
| Married/partnered | 0.75 | 0.48–1.15 | ||
| Prednisone | 0.59 | 0.32–1.09 | ||
| Patient global | 0.989 | 0.979–0.998 | ||
| Patient pain | 0.990 | 0.981–1.000 | ||
| Baseline CDAI (per 5 units) | 0.986 | 0.90–1.08 | ||
| Tender joint count | 0.965 | 0.936–0.995 | ||
| Swollen joint count | 1.048 | 1.014–1.084 | ||
| Calendar year | 0.96 | 0.88–1.04 | ||
↵* mHAQ ranges from 0 to 3 and the minimal clinically important improvement for PsA is about 0.35; a score < 0.3 is considered “normal.” Only patients with mHAQ > 0.3 at baseline were included in this model (n = 462). Among these, 122 achieved a normal mHAQ at followup (26.4%). Model C-statistic = 0.728. BMI: body mass index; PsA: psoriatic arthritis; CDAI: Clinical Disease Activity Index.